Pancragen

Bioregulator

Also known as: KEDW-NH2, Lys-Glu-Asp-Trp-NH2, lysyl-glutamyl-aspartyl-tryptophanamide

Tier 3, Preclinical only

Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.

Half-life

Not established

No absorption/elimination half-life found. Pharmacodynamic persistence noted: glucose-lowering effects in old rhesus monkeys 'partially remained 3 weeks after discontinuation' of a 10-day IM course (PMID 25946840), a persistence observation, not a measured plasma half-life.

Dosing

50 mcg

ANIMAL dosing only: 50 µg per animal, IM, once daily for 10 days in old female rhesus monkeys (PMID 25946840, 28509500). A human study in elderly and type-2-diabetic patients exists (PMID 22448364) but the accessible abstract does not state the human dose, route, or duration, do NOT assume the 50 µg monkey IM dose applies to humans.

Frequency

10-day once-daily course reported in animal studies; human dosing schedule not found on allowed hosts.

Regulatory status

Not approved by FDA/EMA. Sold in Russia as a registered peptide bioregulator/parapharmaceutical, not equivalent to drug approval.

Evidence base

mixed · confidence: medium

Single Russian lineage (Khavinson, Goncharova, Korkushko). Strongest evidence base of the short peptides here: dosed in-vivo studies in old rhesus monkeys (IM 50 µg x 10 days) and streptozotocin-diabetic rats, plus a human study in 30 healthy elderly and 33 type-2-diabetic patients (PMID 22448364) reporting reduced fasting glucose/insulin, but the abstract lacks dose, route, randomization, and blinding detail, so rigor cannot be independently confirmed. Small samples, no non-Russian replication. Sequence Lys-Glu-Asp-Trp-NH2 and MW 575.6 Da confirmed on PubChem (CID 68451868).

Safety

No dedicated human safety/toxicology trial (adverse events, tolerability) found on allowed hosts. The human PMID 22448364 study reports metabolic outcomes but no retrievable safety/adverse-event section. Absence of reported harm is not evidence of safety.

Sources